One Week Sustained In Vivo Therapeutic Release and Safety of Novel Extended-Wear Silicone Hydrogel Contact Lenses.

Autor: DiPasquale SA; OcuMedic, Inc., 107 Gilbreth Parkway, Mullica Hill, NJ, 08062, USA.; Biomimetic & Biohybrid Materials, Biomedical Devices, and Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ, 08028, USA., Wuchte LD; Biomimetic & Biohybrid Materials, Biomedical Devices, and Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ, 08028, USA., Mosley RJ; Biomimetic & Biohybrid Materials, Biomedical Devices, and Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ, 08028, USA., Demarest RM; School of Osteopathic Medicine, Rowan University, Stratford, NJ, 08084, USA., Voyles ML; Veterinary Ophthalmology Services, Nashville, TN, 37204, USA., Byrne ME; OcuMedic, Inc., 107 Gilbreth Parkway, Mullica Hill, NJ, 08062, USA.; Biomimetic & Biohybrid Materials, Biomedical Devices, and Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ, 08028, USA.; Department of Chemical Engineering, Rowan University, Glassboro, NJ, 08028, USA.
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2022 Apr; Vol. 11 (7), pp. e2101263. Date of Electronic Publication: 2021 Sep 14.
DOI: 10.1002/adhm.202101263
Abstrakt: Since the seminal work of Wichterle in 1965 describing the first soft contact lenses and their potential for ocular drug delivery, the field has yet to realize his vision. Maintaining all lens commercial properties combined with a mechanism for controlled drug release of therapeutically relevant concentrations for duration of wear is a major challenge. Here, successful in vivo week-long sustained release of a small molecular weight therapeutic in rabbits from extended-wear silicone hydrogel contact lenses meeting all commercial specifications by utilizing a novel macromolecular memory strategy is reported for the first time. Lens-treated eyes show a continuous, therapeutically relevant bromfenac tear concentration of 256.4 ± 23.1 µg mL -1 for 8 days. Bromday (bromfenac ophthalmic solution, 0.09%, Bausch+Lomb) topical drops exhibit a quick peak concentration of 269.3 ± 85.7 µg mL -1 and 100 min duration. Bioavailability (AUC 0-8days ) and mean residence time of lenses are 26 and 155 times higher than drops, respectively. Lenses are safe, well tolerated, and no corneal histological differences are observed. This work highlights the enormous potential of drug releasing lenses as a platform strategy, and offers a new dropless clinical strategy for post-cataract, uveitis, post-LASIK, and corneal abrasion treatment.
(© 2021 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: